DELTA-CORTEF Drug Patent Profile
When do Delta-cortef patents expire, and when can generic versions of Delta-cortef launch?
Delta-cortef is a drug marketed by Pharmacia And Upjohn and is included in one NDA.
The generic ingredient in DELTA-CORTEF is prednisolone. There is one drug master file entry for this compound. Eleven suppliers are listed for this compound. Additional details are available on the prednisolone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Delta-cortef
A generic version of DELTA-CORTEF was approved as prednisolone by ZHEJIANG XIANJU on May 2nd, 2024.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DELTA-CORTEF?
- What are the global sales for DELTA-CORTEF?
- What is Average Wholesale Price for DELTA-CORTEF?
Summary for DELTA-CORTEF
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 82 |
| Clinical Trials: | 37 |
| Patent Applications: | 4,445 |
| DailyMed Link: | DELTA-CORTEF at DailyMed |
Recent Clinical Trials for DELTA-CORTEF
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of North Carolina, Chapel Hill | Phase 4 |
| University Medical Center Groningen | Early Phase 1 |
| Beth Israel Deaconess Medical Center | Phase 2 |
US Patents and Regulatory Information for DELTA-CORTEF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacia And Upjohn | DELTA-CORTEF | prednisolone | TABLET;ORAL | 009987-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for DELTA-CORTEF
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| LE VET B.V. | Equisolon | Prednisolone | EMEA/V/C/002382Alleviation of inflammatory and clinical parameters associated with recurrent airway obstruction (RAO) in horses, in combination with environmental control. | Authorised | no | no | no | 2014-03-12 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
